Cooperative Agreement NU50DD000113
Award Date 9/30/26
Completion Date 9/29/31
Dollars Obligated $200K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
- The National Institute of Child Health and Human Development awarded $429,000 to The Regents Of The University Of Colorado (University of Colorado-Denver) on August 14, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to characterize Fragile X Syndrome in the human brain using post-mortem human tissue. The research team will study cell-type-specific gene expression in Fragile X Syndrome human brain tissue and investigate length and methylation...
- The National Institute of Mental Health awarded The Leland Stanford Junior University $739,125 for a project grant to decipher the molecular function of fragile X messenger ribonucleoprotein (FMRP) in fragile X syndrome, awarded on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242). The project investigates FMRP's role in translational regulation and its relationship to fragile X syndrome pathogenesis. Fragile X syndrome, the most prevalent form of inherited...
- The National Institute of Child Health and Human Development awarded $3.231 million to Regents of the University of Michigan on September 11, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to support Fragile X Premutations, Mechanisms and Modifiers research conducted in Michigan. The award funds three integrated research projects addressing genetic, pathologic, and environmental factors underlying premutation-associated Fragile X...
- The National Institute of Mental Health awarded Cincinnati Children's Hospital Medical Center $723,817 on August 24, 2026, under the Mental Health Research Grants program (CFDA 93.242) to study fragile X syndrome–associated blood-brain barrier defects and hypervascularization using blood-brain barrier assembloid models derived from patient-induced pluripotent stem cells. The research develops and validates BBB assembloid models combining neural and vascular components from fragile X syndrome and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Cincinnati Children's Hospital Medical Center a $900,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) on September 18, 2025, with an ultimate completion date of August 31, 2030. This mechanistic and translational medicine research initiative addresses critical knowledge gaps in Fragile X Syndrome (FXS) by establishing...
- The National Institute of Mental Health awarded The Children's Hospital Corporation (Boston Children's Hospital) $497,364 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research on therapeutic targeting of proteostasis in Fragile X Syndrome. The work investigates protein degradation mechanisms in Fragile X Syndrome and tests proteasome inhibition as a novel therapeutic strategy. The research interrogates whether increased ubiquitin proteasome system...
- Federal Project Grant Award Summary Emory University received a $430,375 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 1, 2025, with completion expected June 30, 2027. This award funds research investigating membrane trafficking impairments in Fragile X Syndrome (FXS), the most common form of inherited intellectual disability and...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $824,998 under Project Grant R01MH137056 on June 1, 2026, to investigate r-loop-induced CGG contraction as a therapeutic approach for Fragile X Syndrome. The funded research examines how two compounds—a MEK inhibitor and a BRAF inhibitor—reactivate the silenced FMR1 gene by promoting DNA demethylation and forming site-specific r-loops that recruit endogenous DNA repair mechanisms...
- The National Institute on Aging awarded Emory University $430,375 on May 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of N6-methyladenosine (m6a) RNA modification in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) pathogenesis. FXTAS is a progressive, late-onset neurodegenerative disorder affecting carriers of CGG premutation expansions in the FMR1 gene, characterized by tremor, gait ataxia, parkinsonism, cognitive decline, and neuropathological features...
- The National Institute of Child Health and Human Development awarded $1.530085 million to the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. on September 15, 2025, under Cooperative Agreement U54HD122210 for the Batten Disease Clinical Research Consortium Career Enhancement Core, a sub-program within the National Center for Advancing Translational Sciences (CFDA 93.350). The award funds two complementary aims. Aim 1 delivers a structured one-year postgraduate fellowship program in...